Skip to main content
Sansure Biotech Inc. logo

Sansure Biotech Inc. — Investor Relations & Filings

Ticker · 688289 ISIN · CNE1000043J1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 870 across all filing types
Latest filing 2026-04-29 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688289

About Sansure Biotech Inc.

https://www.sansureglobal.com/

Sansure Biotech Inc. specializes in the development and manufacture of molecular diagnostic products and genetic testing solutions. The company utilizes proprietary technologies, such as the "One-tube" fast extraction method and advanced magnetic bead technology, to provide high-sensitivity PCR diagnostic kits. Its product portfolio covers a wide range of clinical applications, including infectious disease screening for hepatitis, respiratory infections, and sexually transmitted infections, as well as oncology and maternal health. Sansure also provides integrated laboratory automation systems, including nucleic acid extractors and real-time PCR instruments, designed to streamline clinical workflows and improve diagnostic efficiency for healthcare providers and research institutions globally.

Recent filings

Filing Released Lang Actions
圣湘生物科技股份有限公司关于聘任公司2026年度财务审计机构及内控审计机构的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the appointment and reappointment of the company's financial audit and internal control audit institutions for the year 2026. It details the auditing firm’s qualifications, personnel, independence, audit fees, and the approval process by the audit committee and board of directors. There are no actual financial statements or audit reports included, only information about the appointment of the audit firm. The document length is 2453 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document is best classified as an Audit Report / Information announcement (AR) because it relates specifically to audit matters and the appointment of auditors, but it is not a full annual report or audit report itself. FY 2026
2026-04-29 Chinese
圣湘生物科技股份有限公司2025年度独立董事述职报告（曹亚）
Board/Management Information Classification · 90% confidence The document is a detailed annual report by an independent director of a company, describing their duties, attendance, and oversight activities during the 2025 fiscal year. It includes references to compliance with laws, internal controls, audit firm engagement, and governance matters. The content is a formal report on the independent director's work and observations rather than an announcement or a brief summary. The document length is 3444 characters, which is relatively short but contains substantive content about the director's duties and assessments, not just a notice or certification. This fits the category of a Management Report or similar detailed governance-related report. However, since it is specifically an independent director's annual duty report, it aligns best with Board/Management Information (MANG), which covers announcements of changes or reports related to the company's board or senior management activities. It is not an Annual Report (10-K), Audit Report (AR), or Remuneration Information (DEF 14A). Therefore, the most appropriate classification is MANG with high confidence.
2026-04-29 Chinese
圣湘生物科技股份有限公司关于2025年度日常关联交易确认及预计2026年度日常关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from 圣湘生物科技股份有限公司 regarding the confirmation of daily related-party transactions for the fiscal year 2025 and the forecast for 2026. It details the nature, amounts, and counterparties of these related-party transactions, the approval process by the board, and the necessity and fairness of these transactions. The document is structured as a formal announcement to shareholders and the public, including a statement that the matter will be submitted for shareholder approval. It does not contain comprehensive financial statements or detailed financial performance data typical of annual or interim reports. It is not a management discussion or earnings release, nor is it a regulatory certification or legal proceeding. The content focuses on disclosure of related-party transactions, which is a regulatory requirement and typically classified under general regulatory announcements. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length (7692 characters) and detailed content support this classification rather than a brief report publication announcement or a full financial report.
2026-04-29 Chinese
圣湘生物科技股份有限公司2025年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2025年度内部控制评价报告' which translates to '2025 Internal Control Evaluation Report'. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2025. The content includes detailed descriptions of internal control scope, standards, defect recognition, and remediation status. It is a formal report on internal control evaluation rather than an announcement or certification. The document length is 3656 characters, which is relatively short but contains substantive content about internal control evaluation, not just a notice or announcement. This type of report fits best under Audit Report / Information (AR) as it relates to internal control evaluation and audit-related information, distinct from a full Annual Report (10-K) or other categories. Therefore, the classification is AR with high confidence. FY 2025
2026-04-29 Chinese
中审众环会计师事务所（特殊普通合伙）关于圣湘生物科技股份有限公司2025年度非经营性资金占用及其他关联资金往来情况汇总表的专项审核报告
Audit Report / Information Classification · 95% confidence The document is a specialized audit report issued by Zhongshen Zhonghuan Certified Public Accountants LLP regarding the non-operating fund occupation and other related party fund transactions of Shengxiang Biotechnology Co., Ltd. for the fiscal year ending December 31, 2025. It includes detailed tables summarizing these transactions and is explicitly described as a "专项审核报告" (special audit report) related to a specific aspect of the company's financials, not the full annual report. The document references compliance with Chinese securities regulatory guidelines and auditing standards, and it provides an auditor's opinion on the specific financial data related to non-operating fund occupation and related party transactions. It is not a full annual report (10-K), nor a general audit report of the entire financial statements, but a standalone audit report on a particular issue. The document length (5801 characters) and content confirm it is a full report, not just an announcement or certification. Therefore, the most appropriate classification is Audit Report / Information (AR). FY 2025
2026-04-29 Chinese
圣湘生物科技股份有限公司关于作废2023年限制性股票激励计划部分已授予尚未归属的限制性股票的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from the company regarding the cancellation of part of the 2023 restricted stock incentive plan, specifically the cancellation of unvested restricted shares due to an employee's departure. It details board meetings, approvals, legal opinions, and compliance with relevant laws and regulations. The document does not contain financial statements or detailed financial performance data, nor is it a report or presentation. It is a regulatory announcement about changes in the company's stock incentive plan, which relates to share-based compensation and corporate governance matters. This fits best under the category of Regulatory Filings (RNS), as it is a formal disclosure of corporate actions and compliance but not a full report or financial statement.
2026-04-29 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.